Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.88% | 202.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.88% | 202.56% | |||
| Cost of Revenue | -15.64% | 386.92% | |||
| Gross Profit | 1.10% | 111.20% | |||
| SG&A Expenses | -15.08% | 12.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.13% | 22.31% | |||
| Operating Income | 16.94% | -6.78% | |||
| Income Before Tax | 9.72% | -1.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.72% | -1.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.72% | -1.65% | |||
| EBIT | 16.94% | -6.78% | |||
| EBITDA | 16.95% | -6.80% | |||
| EPS Basic | 10.53% | -2.70% | |||
| Normalized Basic EPS | 12.50% | -4.35% | |||
| EPS Diluted | 10.53% | -2.70% | |||
| Normalized Diluted EPS | 12.50% | -4.35% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
